Think Bold. Think Scientific. Think Veristat.

Experts Who Make the Impossible Possible

In 2022, Veristat teams supported marketing applications for eight therapies that received regulatory approval, the majority for therapies designed to treat rare diseases.  


LEARN MORE
rare-disease760+ Rare Disease Clinical Trials
regulatory-approval160+ Marketing Applications
experience12% of 2021 FDA Approvals
Veristat Supports 8 Approvals in 2022

READ PRESS RELEASE
Upcoming Webinars

LEARN MORE
Congratulations to HIPRA on EMA Approval
Home Page_HIPRA PR-2

READ PRESS RELEASE

Specialty Expertise

Our team of scientific experts is easy to work with, even for the rarest, most complex, and never done before novel therapies.

Cell & Gene Therapies
COVID-19
Oncology
Regulatory Affairs
Decentralized Trials
All Services

Driving Success

I am grateful for the dedication, excitement and clinical trial expertise that the Veristat team provided for our program. Veristat's collaboration was critical to the successful clinical trials that led to our product's approval.
President of Research and Development
Mid-Size Pharma
Counting on Veristat for the preparation of our New Drug Application (NDA) is the culmination of years of hard work and dedication by the Veristat team. I have truly come to rely on the clinical and statistical expertise of Veristat over the past decade.
Chief Executive Officer
Mid-Size Pharma
I wanted to let you know the protocol has been fully approved and is now considered final. We could not have done this without you, and we are grateful for your significant contributions.
Head of Regulatory & Medical Writing
Small Pharma
Let me express my gratitude to the Veristat team for publishing our MAA…67 days from database lock to filing! This is quite an accomplishment. It has truly been a privilege to work with Veristat on this important milestone for our patients.
Director, Regulatory Operations
Clinical Stage Biopharmaceutical
Thank you Veristat for your close collaboration and attentiveness during our virtual inspection with the Japan PMDA. They have no further questions at this point about our jNDA.
Sr Director of Statistical Programming
Mid-Size Biopharmaceutical

Tackling Problems Big or Small ? We Can Help

Veristat-4-Phases-June-22

 


What Are Your Challenges?

WE CAN HELP

lindsey-lukis-50

Lindsey Lukis
EVP Talent and Culture

 

It's no secret that the nature of our work can be demanding at times. That's because the stakes are high. Our employees are intelligent, passionate, dedicated people who understand their work truly makes a difference. They are helping to extend and save lives, and that purpose binds us all.

CAREERS